These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15558712)

  • 21. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
    Yu ML; Dai CY; Lin ZY; Lee LP; Hou NJ; Hsieh MY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Liver Int; 2006 Feb; 26(1):73-81. PubMed ID: 16420512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
    J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
    Hopkins S; Lambourne J; Farrell G; McCullagh L; Hennessy M; Clarke S; Mulcahy F; Bergin C
    HIV Med; 2006 May; 7(4):248-54. PubMed ID: 16630037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
    Pedersen C; Alsiö Å; Lagging M; Langeland N; Färkkilä M; Buhl MR; Mørch K; Westin J; Sangfelt P; Norkrans G; Christensen PB;
    J Viral Hepat; 2011 Apr; 18(4):245-51. PubMed ID: 20384961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
    Bruno S; Cammà C; Di Marco V; Rumi M; Vinci M; Camozzi M; Rebucci C; Di Bona D; Colombo M; Craxì A; Mondelli MU; Pinzello G
    J Hepatol; 2004 Sep; 41(3):474-81. PubMed ID: 15336451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
    Crespo M; Sauleda S; Esteban JI; Juarez A; Ribera E; Andreu AL; Falco V; Quer J; Ocaña I; Ruiz I; Buti M; Pahissa A; Esteban R; Guardia J
    J Viral Hepat; 2007 Apr; 14(4):228-38. PubMed ID: 17381714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of individualized treatment for hepatitis C patients in the real world.
    Chen TM; Huang PT; Lin CH; Tsai MH; Lin LF; Liu CC; Ho KS; Tung JN
    J Gastroenterol Hepatol; 2010 Jan; 25(1):61-9. PubMed ID: 19780879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conventional interferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3.
    Farooqi JI; Farooqi RJ
    J Coll Physicians Surg Pak; 2008 Oct; 18(10):620-4. PubMed ID: 18940119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
    Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
    Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
    Kamal SM; El Kamary SS; Shardell MD; Hashem M; Ahmed IN; Muhammadi M; Sayed K; Moustafa A; Hakem SA; Ibrahiem A; Moniem M; Mansour H; Abdelaziz M
    Hepatology; 2007 Dec; 46(6):1732-40. PubMed ID: 17943989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.
    Bain VG; Lee SS; Peltekian K; Yoshida EM; Deschênes M; Sherman M; Bailey R; Witt-Sullivan H; Balshaw R; Krajden M;
    Aliment Pharmacol Ther; 2008 Jul; 28(1):43-50. PubMed ID: 18397386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.
    Sezaki H; Suzuki F; Akuta N; Yatsuji H; Hosaka T; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    Intervirology; 2009; 52(1):43-8. PubMed ID: 19372703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.
    Lee SS; Ferenci P
    Antivir Ther; 2008; 13 Suppl 1():9-16. PubMed ID: 18432158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
    Chevaliez S; Hézode C; Soulier A; Costes B; Bouvier-Alias M; Rouanet S; Foucher J; Bronowicki JP; Tran A; Rosa I; Mathurin P; Alric L; Leroy V; Couzigou P; Mallat A; Charaf-Eddine M; Babany G; Pawlotsky JM
    Gastroenterology; 2011 Jul; 141(1):119-27. PubMed ID: 21439960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hepatitis C--treatment of untreated (naive) patients].
    Duvnjak M; Pavić T; Tomasić V; Lerotić I; Virović L
    Acta Med Croatica; 2005; 59(5):453-61. PubMed ID: 16381243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin.
    Kowala-Piaskowska A; Słuzewski W; Figlerowicz M; Mozer-Lisewska I
    Infection; 2007 Jun; 35(3):175-9. PubMed ID: 17565459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.
    Gad RR; Males S; El Makhzangy H; Shouman S; Hasan A; Attala M; El Hoseiny M; Zalata K; Abdel-Hamid M; Fontanet A; Mohamed MK; Esmat G
    Liver Int; 2008 Sep; 28(8):1112-9. PubMed ID: 18397226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
    Elefsiniotis IS; Pavlidis C; Ketikoglou I; Koutsounas S; Scarmeas N; Pantazis KD; Moulakakis A; Tsianos EV
    Eur J Intern Med; 2008 Jun; 19(4):266-70. PubMed ID: 18471675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.